Precision Medicine Approaches When Prostate Cancer Akts Up

Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.

See related article by de Bono et al., p. 928

http://bit.ly/2HK21j9